人物专栏:刘允怡

Professor Lau is currently Professor, Divisionof Hepato-Pancreato-Biliary Surgery, Departmentof Surgery, The Chinese University of Hong Kong;Honoarary Consultant in Hepato-pancreato-bilia-ry Surgery in hospitals under the New TerritoriesEast Cluster (whic…     

Biographies of Invited Authors

Dr. David Madoff is Chief of the Division of Interventional Radiology and Professor of Radiology at New Oncork-Presbyterian/Weill Cornell Medical Center. He is an internationally-recognized expert in ]nterventional Oncology with a particular interest in treating liver cancer. Prior to joining Weill Cornell in 2011, he spent more than a decade as faculty at The University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Madoff is world-renowned for his work on preoperative portal vein embolization, a technique used to im- prove the safety of major hepatic resection. Dr. Madoff also treats patients with transarterial and ablative ap-proaches for cancer in the liver and other organ systems.     

腺病毒介导的大肠杆菌CD自杀基因体内外对肿瘤杀伤作用的研究

编委会 Editorial Board名誉主编 Honorary Editor-in-chief吴孟超 Wu Meng chao(Second Military Medical University,Shanghai 200433学术顾问 Academic Advisers巴德年 Ba Denian(Chinese Academy of Medical Sciences,Beijing 100730)刘新垣 Liu Xinyuan(Shanghai Institute of Biochemistry,Chinese Academy of Sciences,Shanghai 200031)吴旻 WuMin(Cancer Institute,Chinese Academy of Medical Sciences,Beijing 100021)汤钊猷 Tang Zhaoyou(Shanghai Medical University,Shanghai 200032)主编 Editor-in-chief张友会 Zhang Youhui(Cancer Institute,Chinese Academy of Medical Sciences,Beijing,100021)副主编 Associate Editor-in-chief崔正言 Cul Zhenyan(Department of Immunology,Shandong Academy of Medical Sciences,Jinan 250001)钱振超 Qian Zhenchao(Department of Patho-physiology,Dalian Medical University,Dalian 116027)何球藻 He Qiuzao(Department of Immunology,Shanghai Medical University,Shanghai 200032)董志伟 Dong Zhiwei(Cancer Institute,Chinese Academy of Medical Sciences,Beijing 100021)常务副主编 Managing Editor-in-chief     

The 3rd Guangzhou International Symposium on Oncology Guangzhou November 7-9,2013

正Confirmed Speakers:Boris Pasche(The University of Alabama at Birmingham,USA)Wei Zhang(MD Anderson Cancer Center,USA)Joseph Wee(National Cancer Center Singapore)Shiyuan Cheng(Northwestern University Feinberg School of Medicine,USA)Ilya Shmulevich(Genome Data Analysis Center,USA)Zhimin Lu(MD Anderson Cancer Center,USA)Brittany Parker(MD Anderson Cancer Center,USA)Olli Yli-Harja(Tampere University of Technology,Finland)     

《中国肿瘤生物治疗杂志》

编委会 Editorial Board 名誉主编 Honorary Editor - in - chief 吴孟超 Wu Mengchao (Second Military Medical University, Shanghai 200433) 学术顾问 Academic Advisers 巴德年 Ba Denian (Chinese Academy of Medical Sciences, Beijing 100730) 刘新垣 Liu Xinyuan(Shanghai Institute of Biochemistry, Chinese Academy of Sciences, Shanghai 200031) 吴旻 Wu Min(Cancer Institute, Chinese Academy of Medical Sciences, Beijing 100021) 汤钊猷 Tang Zhaoyou (Shanghai Medical University, Shanghai 200032) 主编 Editor-in-chief 张友会 Zhang Youhui(Cancer Institute, Chinese Academy of Medical Sciences, Beijing 100021) 副主编 Asscoiate Editor- in- chief 崔正言 Cui Zhenyan (Department of Immunology, Shangdong Academy of Medical Sciences, Jinan 250001) 钱振超 Qian Zhenchao(Department of Patho-physiology, Dalian Medical University, Dalian 116027) 何球藻 He Qiuzao (Department of Immunology, Shanghai Medical University, Shanghai 200032) 董志伟 Dong Zhiwei (Cancer Institute, Chinese Academy of Medical Sciences, Beijing 100021)     

《中国肿瘤生物治疗杂志》

编委会 Editorial Board 名誉主编 Honorary Editor - in - chief 吴孟超 Wu Mengchao (Second Military Medical University, Shanghai 200433) 学术顾问 Academic Advisers 巴德年 Ba Denian (Chinese Academy of Medical Sciences, Beijing 100730) 刘新垣 Liu Xinyuan (Shanghai Institute of Biochemistry, Chinese Academy of Sciences, Shanghai 200031) 吴旻 Wu Min (Cancer Institute, Chinese Academy of Medical Sciences, Beijing 100021) 汤钊猷 Tang Zhaoyou (Shanghai Medical University, Shanghai 200032) 主编 Editor - in - chief 张友会 Zhang Youhui(Cancer Institute, Chinese Academy of Medical Sciences, Beijing 100021) 副主编 Asscoiate Editor - in - chief 崔正言 Cui Zhenyan (Department of Immunology, Shangdong Academy of Medical Sciences, Jinan 250001) 钱振超 Qian Zhenchao (Department of Patho - physiology, Dalian Medical University, Dalian 116027) 何球藻 He Qiuzao (Department of Immunology, Shanghai Medical University, Shanghai 200032) 董志伟 Dong Zhiwei(Cancer Institute, Chinese Academy of Medical Sciences, Beiji     

Phase II study of carboplatin in patients with nonresected lung cancer

Summary A multicenter phase II trial of carboplatin, a new platinum analog of cisplatin, was carried out in bronchogenic carcinoma at 17 institutions throughout Japan. Of 139 patients enrolled in this trial, 10 were excluded from analysis as inevaluable and the remaining 129 were judged to be evaluable for response and toxic effects by the Extramural Review Committee. Patients were treated i. v. with either 300 or 400 mg/m² carboplatin every 4 weeks. Responses and toxic effects were assessed at both dose levels. The overall response rate was 17.8% (23/129), with response rates of 28.4% (19/67) for small-cell disease, 7.1% (2/28) for squamous-cell carcinoma, and 6.9% (2/29) for adenocarcinoma. The most frequent toxic effects were thrombocytopenia and leukopenia, with a platelet count of <7 × 10⁴ μl recorded in 60 patients (46.5%) and a WBC count of <3,000/μl recorded in 60 cases (46.5%). Vormiting occurred in 28 patients (21.7%). Renal, aural, and neurotoxicities were not seen. Hydration was not required. Carboplatin was demonstrated to be active against lung cancer, especially against small-cell lung cancer. Participating members: Kiyoji Kimura, Nagoya Memorial Hospital; Akira Suzuki, Sapporo Medical College; Kiyosi Konno, The Research Institute for Tuberculosis and Cancer, Tohoku University; Kotaro Oizumi², The Research Institute for Tuberculosis and Cancer, Tohoku University; Koich Hasegawa, Tsuboi Hospital; Takeshi Honma, Saitama Cancer Center; Toshiro Ogata, National Defence Medical College School of Medicine; Yutaka Nisiwaki², Matsudo National Hospital: Takayuki Kuriyama, Institute of Pulmonary Cancer Research. School of Medicine, University of Chiba; Hisanobu Niitani¹, Nippon Medical School; Kenji Eguchi³, National Cancer Center; Yasunobu Kuraishi, The Jikei University School of Medicine; Makoto Ogawa, Japanese Foundation for Cancer Research; Kazuo Ohta, Aichi Cancer Center: Shunsaku Oshima², Chest Disease Research Institute, Kyoto University; Masahiro Fukuoka², Osaka Prefectural Habikino Hospital; Kiyoyuki Furuse², Kinki National Center Hospital; Ikuro Kimura, Okayama University medical School; Taisuke Onoshi², Okayama University medical School; Mitsuo Ohta, National Kyushu Cancer Center; Nobuyuki Hara², National Kyushu Cancer Center Chairman for lung cancer Reviewer Extramural reviewer Offprint requests to: H. Niitani, Department of Clinical Pathology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113, Japan     

Tianjin Medical University Cancer Institute and Hospital

Tianjin Medical University Cancer Institute and Hospital (TMUCIH) is the birthplace of Oncology in China.     

Personage Column: Prof. Jrg F. Debatin, M.D., MBA

Born in 1961 in Bonn, Germany, Jrg F. Debatin stud-ied medicine at the Medical School of the University of Heidelberg where he graduated in 1987. He completed his residency in Diagnostic Radiology at Duke University Medical Center and subsequently moved to Stanford Uni-versity Medical Center for fellowship in Abdominal Im-aging. As a diplomate of the American Board of Radiology he took up a position as Associate Professor of Radiology and Chief of Magnetic Resonance Imaging in July 1993 at Zürich University Hospital. He was appointed Professor and Chairman of the Department of Diagnostic and Inter-ventional Radiology at the University Hospital in Essen in August 1999. Here he built a most powerful clinical and research organization, impacting the course of Diag-nostic Radiology throughout the world.     

The Brief Introduction to Tianjin Medical University Cancer and Hospital

Tianjin Medical University Cancer Institute and Hospital (TMUCIH) is the birthplace of Oncology in China. It has a history of more than a hundred years and has     

Tianjin Medical University Cancer Institute and Hospital

Tianjin Medical University Cancer Institute and Hospital (TMUCIH) is the birthplace of Oncology in China. It has a history of more than a hundred years and has become one of the most famous modernized     

Personage Column： Prof. Jǒrg F. Debatin, M.D., MBA

Born in 1961 in Bonn, Germany, Jǒrg F. Debatin stud- ied medicine at the Medical School of the University of Heidelberg where he graduated in 1987. He completed his residency in Diagnostic Radiology at Duke University Medical Center and subsequently moved to Stanford University Medical Center for fellowship in Abdominal Imaging. As a diplomate of the American Board of Radiology he took up a position as Associate Professor of Radiology and Chief of Magnetic Resonance Imaging in July 1993 at Ziirich University Hospital. He was appointed Professor and Chairman of the Department of Diagnostic and Interventional Radiology at the University Hospital in Essen in August 1999. Here he built a most powerful clinical and research organization, impacting the course of Diagnostic Radiology throughout the world.     

Personage Column： Prof. Li Zhang, M.D.

Education and training experience After gaining his medical degree from Medical school of Sun Yat-Sen University （SYSU） and board certification as a physician of medical oncology, prof. Li Zhang continued with his post-graduate training at Cancer Centre of Sun Yat-Sen University （CCSYSU）. After completing a master＇s degree of clinical oncology, he subsequently works at CCSYSU as attending doctor, associated professor and now as professor of Medical Oncology Department, Vice chairmen of Medical Oncology Department and Deputy Director of National Clinical Study （GCP） centre for anti-cancer drugs at Cancer Centre of Sun Yat- Sen University.     

Adenosquamous Carcinoma of Colon and Rectum

In colon and rectum, adenosquamous carcinoma is extremely rare. 6 patients with adenosquamous carcinoma of colon and rectum were identified by Tianjin Medical University Cancer Hospital from Jan. 1967 to Dec. 1997. 2 male and 4 female had a median age of 48 (range, 40-60) years. All patients were treated surgically. The pathology confirmed the diagnosis of adeno-squamous carcinoma, that was 0.19% (6/3098) with colorectal adenocarcinoma during the same period. The clinical symptom was nearly…     

ESTABLISHMENT OF INTRAPERITONEAL TRANSPLANTATION MODEL OF CISPLATIN-RESISTANT OVARIAN CARCINOMA CELL IN SCID MICE

MATERIALS AND METHODS Experimental Animal Six-eight week-old female C.B17/SCID mice, feed in the environment of specific-pathogen free, wereobtained from Experimental animal Center of National Institute for the Control of pharmaceutical and biological products. Cells Ovary serosity papillary adenocarcinoma cell line SKOV3 was obtained from the Obstetrics and Gynecology Hospital Medical Center of Fudan University; The cisplantin multidrug resistant ovarian cancer cell SKOV3/C…     

肝脏移植治疗肝癌的价值——附巨大肝癌肝脏移植一例报道

随着肝移植技术的日臻成熟以及器官保存液(University of Wiscontion，UW)和各种免疫抑制剂的应用，肝移植手术的成功率及术后1年成活率逐渐增高。我们于2002年8月成功为—巨大肝癌患者实施了原位肝移植，目前患者状况良好，报道如下。     

General Information of Tianjin Lung Cancer Institute

The precursor of Tianjin Lung Cancer Institute was the Key Laboratory of Lung Cancer Molecular Biology of Sichuan Province,founded in 1994 by the West China University of Medical Sciences,that is the top-level Medical University in China,founded by the joint effects of Christian missions from the United States of American,Great Britain and Canada in 1892.The whole Key Laboratory was moved to